Vonomac 20 Tablet 10

VONOMAC 20 TABLET 10 can interact with the following medications:

• Antiretrovirals such as rilpivirine, atazanavir, and nelfinavir: Vonoprazan reduces stomach acidity, potentially altering the absorption of these antiretroviral medications, which could affect their effectiveness and safety.
• CYP3A Substrates such as verapamil or cyclosporine: Vonoprazan weakly inhibits CYP3A enzymes, which may increase the concentration of CYP3A4 substrates in the body, potentially leading to adverse reactions.
• CYP2C19 Substrates such as clopidogrel, citalopram, and cilostazol: Vonoprazan inhibits CYP2C19 enzymes, which can alter the metabolism of these medicines, affecting their efficacy. 
• Strong or Moderate CYP3A4 Inducers such as phenytoin: Strong or moderate CYP3A inducers reduce Vonoprazan exposure, potentially reducing its effectiveness in treating conditions for which it is prescribed. 
• Other medications such as iron salts: Vonoprazan may reduce the absorption of iron, impacting its therapeutic benefits.
• Cancer medications such as erlotinib, and dasatinib: Vonoprazan decreases stomach acidity, which may reduce the absorption of these medications, impacting their effect.

VONOMAC 20 TABLET 10 may interact with the following diseases:

• Gastric Malignancy: Vonoprazan may mask symptoms of gastric malignancy (stomach cancer), delaying diagnosis and treatment.
• Acute Tubulointerstitial Nephritis: Vonoprazan may increase the risk of acute tubulointerstitial nephritis, a kidney disorder, especially with prolonged use.
• Clostridioides difficile-Associated Diarrhea (CDAD): Use of Vonoprazan may increase the risk of Clostridioides difficile-associated diarrhoea, a potentially severe infection of the colon.
• Bone Fracture, including Osteoporosis-related Fracture: Long-term use of Vonoprazan may increase the risk of bone fractures, including those related to osteoporosis, due to potential effects on calcium absorption and bone density.
• Vitamin B12 (Cobalamin) Deficiency: Vonoprazan can reduce the absorption of vitamin B12, leading to deficiency over time, especially in long-term users.
• Hypomagnesemia and Mineral Metabolism: Prolonged use of Vonoprazan may lead to hypomagnesemia (low magnesium levels) and affect mineral metabolism, which can have various health implications.
• Fundic Gland Polyps: Vonoprazan use has been associated with an increased risk of fundic gland polyps, which are benign growths in the stomach.

The recommended daily dose of VONOMAC 20 TABLET 10 is typically taken as prescribed by the doctor. Follow the dosage instructions provided by your doctor. The dosage may vary depending on the severity of the condition and individual response to treatment. Do not alter the prescribed dosage without consulting your doctor.

In case of accidental overdose, do not delay and seek immediate medical attention.

If you forget to take a dose of VONOMAC 20 TABLET 10, take it as soon as you remember. However, if it is close to the time for your next dose, skip the missed dose and continue with your regular dosing schedule. Avoid taking a double dose to compensate for the missed one. Always follow the instructions given by your doctor.